Hepbest 25mg Tenofovir Alafenamide Tablets

HepBest 25mg Tenofovir Alafenamide Tablet is the first drug in eight years that got approved for the management of chronic hepatitis B in India. HEPBEST -Tenofovir alafenamide fumarate tablet (TAF) is a nucleotide reverse transcriptase inhibitor. Moreover, it is a novel ester prodrug of the antiretroviral tenofovir that is to be used in the treatment of HIV infection and chronic hepatitis B. The treatment is applied in the form of tenofovir alafenamide fumarate (TAF). However, it is closely related to the commonly used reverse-transcriptase inhibitor TDF (tenofovir disoproxil fumarate).

Although, tenofovir disoproxil fumarate (TDF) has a good safety profile and efficacy, and it is also currently a cornerstone of HIV antiviral treatment. But its use has been associated with nephrotoxicity which causes reduced bone mineral density. In case of TAF it has been shown to have improved antiviral efficacy as well as enhanced delivery of TFV into peripheral blood mononuclear cells (PBMCs) and lymphatic tissues have a higher barrier to resistance and a much improved safety profile. Improved renal safety is likely attributable to lower circulating plasma concentrations of tenofovir and therefore less exposure and damage to bone and the kidneys, where tenofovir is metabolized.

According to World Health Organization there are more than 2 billion people worldwide who are infected with the HBV (hepatitis B virus) and among them more than 240 million people are infected with chronic liver infection.

• The patients with liver infections are at risk of developing serious illness or in some cases of death also. The serious illnesses are largely resulting from liver cirrhosis and liver cancer. HepBestTM (TAF) is the first drug that got to be approved for the management of chronic hepatitis B in India in the last 8 years.
• TAF has greater plasma stability. Moreover, TAF has more efficacy as compared to earlier formulation of tenofovir (TDF) with an enhanced renal and bone safety profile.
• Mylan continues to be in the forefront when it comes to introduce new treatments for the management of hepatitis in India. After bringing the best drug for hepatitis B management, the TAF (HepBest Tenofovir alafenamide fumarate) tablet to India, now Mylan hopes to provide care for the patients of chronic hepatitis B and to improve the overall management of the disease.”

The Hepbest TAF Treatment Duration

Adults and adolescents (aged 12 years and older with body weight at least 35 kg): one tablet once daily.

In case of Treatment discontinuation:

Treatment discontinuation may be considered as follows:

• In HBeAgpositive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with antiHBe detection) is confirmed or until HBs seroconversion or until there is loss of efficacy . Regular reassessment is recommended after treatment discontinuation to detect virological relapse.

• In HBeAgnegative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or until there is evidence of loss of efficacy. If the treatment is prolonged i.e. for more than 2 years then regular reassessment is recommended so that patients can confirm that the selected therapy is still that appropriate for the patient or not.

Missed dose: If a dose is missed and less than 18 hours have passed from the time it is usually taken, the patient should take Tenofovir Alafenamide tablets 25 mg as soon as possible and then resume their normal dosing schedule. If more than 18 hours have passed from the time it is usually taken, the patient should not take the missed dose and should simply resume the normal dosing schedule.

There are some cases where patients vomit. When patient vomits within 1 hour of taking the TAF tablets, then the patient need to take another tablet but If the patient vomits more than one hour after taking TAF Tablet the patient does not need to take another tablet.